|
gptkbp:instanceOf
|
benzodiazepine
sedative
anticonvulsant
World Health Organization essential medicine
|
|
gptkbp:ATCCode
|
N03AA02
|
|
gptkbp:brand
|
gptkb:Luminal
gptkb:Phenobarbitone
gptkb:Solfoton
|
|
gptkbp:CASNumber
|
50-06-6
|
|
gptkbp:chemicalFormula
|
C12H12N2O3
|
|
gptkbp:contraindication
|
porphyria
hypersensitivity to barbiturates
severe respiratory depression
|
|
gptkbp:discoveredBy
|
gptkb:Heinrich_Emil_Fischer
|
|
gptkbp:discoveredIn
|
1912
|
|
gptkbp:eliminationHalfLife
|
53–118 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenobarbital
|
|
gptkbp:isomerOf
|
gptkb:methylphenobarbital
|
|
gptkbp:IUPACName
|
5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
|
|
gptkbp:legalStatus
|
Schedule IV (US)
Prescription only (various countries)
|
|
gptkbp:marketedAs
|
1912
|
|
gptkbp:mechanismOfAction
|
positive allosteric modulator of GABAA receptor
CNS depressant
|
|
gptkbp:meltingPoint
|
174 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
232.24 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
4763
CHEMBL41
DB01174
|
|
gptkbp:riskFactor
|
addiction
overdose
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
cognitive impairment
drowsiness
respiratory depression
dependence
|
|
gptkbp:solubility
|
1.2 g/L at 25 °C
|
|
gptkbp:UNII
|
Y3J0XW6W98
|
|
gptkbp:usedFor
|
gptkb:seizure
epilepsy
anxiety
insomnia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Epileptic_Dogs
gptkb:Schedule_IV
|
|
gptkbp:bfsLayer
|
6
|